Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Link of Obesity With Primary Aldosteronism: Causal or Not?

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Controversies, Challenges, and Dilemmas in Primary Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Sodium, Potassium and Calories: Implications for Implementing a Recommended Diet in Adults with Hypertension.

American journal of hypertension·2026
Same author

Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

From Race-Based to Equity-Informed Antihypertensive Medication Selection: Rationale for the 2025 AHA/ACC Guideline Change.

Circulation·2026
Same author

Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. Reply.

The New England journal of medicine·2026
Same journal

Antihypertensive Efficacy, Safety, and Adherence After Switching From a Free Combination of Bisoprolol/Metoprolol and Amlodipine to Bisoprolol/Amlodipine FDC Tablets (5/5 mg) in Chinese Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Blood Pressure Variability in Acute Ischemic Stroke: Current Evidence, Measurement Challenges, and Future Directions.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Association of Triglyceride-Glucose Index, Triglyceride/HDL Cholesterol Ratio and Metabolic Score for Insulin Resistance With Asymptomatic Organ Damage in Previously Untreated Patients With Hypertension.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Letter to the Editor Regarding: "Associations of High-Sensitivity Cardiac Troponin and N-Terminal Pro-B-Type Natriuretic Peptide With Echocardiographic Features in Patients With Hypertension".

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Relationship of Carotid-Femoral Pulse Wave Velocity and Brachial-Ankle Pulse Wave Velocity With the Risk of New-Onset Cardiovascular Events: A Cohort Study in the Beijing Community-Based Population.

Journal of clinical hypertension (Greenwich, Conn.)·2026
Same journal

Oral Health and Cardiovascular Disease Among Hypertensive Medicated Adults With Uncontrolled Blood Pressure.

Journal of clinical hypertension (Greenwich, Conn.)·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Alpha 1 adrenoreceptor antagonists.

Richard H Grimm1, John M Flack

  • 1Cardiolgy and Epidemiology, University of Minnesota, Minneapolis, MN, USA. grimm001@umn.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|September 8, 2011
PubMed
Summary
This summary is machine-generated.

Alpha-1 (α(1)) antagonists lower blood pressure by blocking specific receptors. They are not first-line treatments but can be effective adjuncts, especially when combined with diuretics, and benefit men with benign prostatic hypertrophy.

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 29, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Urology

Background:

  • Alpha-1 (α(1)) antagonists selectively block post-synaptic α(1)-adrenoreceptors.
  • This action antagonizes catecholamine-induced constriction in vascular beds.

Purpose of the Study:

  • To outline the clinical utility and practical recommendations for alpha-1 (α(1)) antagonists.
  • To discuss their role in antihypertensive therapy and management of benign prostatic hypertrophy.

Main Methods:

  • Review of pharmacological actions of α(1)-adrenoreceptor antagonists.
  • Analysis of their use in combination with other antihypertensive agents, particularly diuretics.
  • Evaluation of their efficacy and contraindications in specific patient populations.

Main Results:

  • α(1)-Adrenoreceptor antagonists are not first-line for hypertension but are effective add-on therapies, preferably with diuretics.
  • Combination with diuretics mitigates fluid expansion and enhances blood pressure reduction.
  • These agents improve urinary flow and reduce lower urinary tract symptoms in men with benign prostatic hypertrophy.

Conclusions:

  • α(1)-Adrenoreceptor antagonists are valuable adjuncts in hypertension management, particularly when combined with diuretics.
  • They offer significant benefits for men with benign prostatic hypertrophy.
  • Contraindicated in heart failure due to potential for fluid volume expansion.